Disease Overview：Diminished Ovarian Reserve（DOR）
Diminished ovarian reserve (DOR) is a clinical condition characterized by a reduction in the quantity and/or quality of remaining oocytes, leading to impaired reproductive potential. It is commonly diagnosed through elevated follicle-stimulating hormone (FSH) levels on cycle day 2–3, low anti-Müllerian hormone (AMH) concentrations (<1.0 ng/mL), and reduced antral follicle count (AFC <5–7) on transvaginal ultrasound. DOR may occur idiopathically or secondary to factors such as advanced maternal age, genetic predisposition (e.g., FMR1 premutation), prior gonadotoxic treatments, or autoimmune conditions. While not synonymous with premature ovarian insufficiency (POI), DOR significantly lowers natural conception rates and reduces response to ovarian stimulation during assisted reproductive technology (ART) cycles—often resulting in fewer retrieved oocytes, higher cycle cancellation rates, and diminished live birth outcomes.
China offers distinct advantages for international patients seeking DOR management. Leading reproductive medicine centers—many accredited by ISO and certified under China’s National Assisted Reproductive Technology (ART) Regulations—employ evidence-based protocols, including individualized ovarian stimulation regimens, mitochondrial augmentation techniques, and integrated traditional Chinese medicine (TCM) adjuncts supported by peer-reviewed studies. Advanced equipment such as time-lapse embryo imaging systems and next-generation sequencing for preimplantation genetic testing (PGT-A) enhances embryo selection accuracy. Clinical data from tier-1 hospitals report cumulative live birth rates of 42–58% per initiated IVF cycle in DOR patients aged <38, comparable to top global programs—yet at approximately 40–60% lower total treatment costs than in the US or Western Europe. As a dedicated medical tourism agency, we facilitate seamless access: coordinating appointments with board-certified reproductive endocrinologists, verifying hospital credentials, providing itemized, transparent pricing in advance, and delivering end-to-end support—from visa assistance and accommodation to bilingual nursing liaison and post-treatment follow-up.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Diminished Ovarian Reserve (DOR)
Non-Surgical / Conservative / Medication Options
*Target Criteria:* AMH < 1.1 ng/mL, AFC < 5, FSH > 10 IU/L; no contraindications to hormonal modulation or ovarian stimulation.
- •Lifestyle & Nutritional Intervention
- CoQ10 (600 mg/day) + DHEA (25 mg/day) 3-month supply (brand-name, hospital-pharmacy dispensed): $145–$195
- •Ovarian Stimulation Protocols (for natural cycle monitoring or IVF prep)
- Letrozole (5-day course, transvaginal ultrasound + E2/P4 monitoring × 3 visits): $130–$175 - Gonadotropin protocol (rFSH/HMG, 7–10 days, 4–5 ultrasounds + 3 hormone assays): $420–$680
- •Adjunctive Pharmacotherapy
- Low-dose aspirin + heparin (if thrombophilia screening positive): $65–$95
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Confirmed DOR with prior failed stimulation; exclusion of premature ovarian insufficiency (POI); normal karyotype & FMR1 testing; BMI < 35.
- •Ovarian Rejuvenation (PRP Intraovarian Injection)
- PRP preparation + bilateral intraovarian ultrasound-guided injection: $1,150–$1,480 - Post-procedure monitoring (E2/FSH × 2, AFC at 8 weeks): $165–$210
- •Mitochondrial Augmentation (Autologous Mitochondrial Transfer – experimental, only in approved clinical trials)
- Oocyte retrieval + mitochondrial transfer + embryo culture: $2,800–$3,450
Special / Complex Condition Management
- •DOR + Endometriosis Stage III/IV: Laparoscopic cystectomy + post-op GnRH agonist × 3 months + IVF: $4,200–$5,600
- •DOR + Autoimmune Thyroiditis (positive TPOAb): Levothyroxine titration + IVF with immunomodulation (IVIG or prednisone taper): $3,750–$4,900
- •Genetic DOR (FMR1 premutation carriers): Preimplantation genetic testing for monogenic disorders (PGT-M) + IVF: $5,100–$6,300
Quick Selection Guide
- •Age < 35, AMH 0.8–1.1 ng/mL, budget <$1,500: Start with letrozole + CoQ10/DHEA + lifestyle optimization ($315–$470)
- •Age 36–40, AMH 0.4–0.7 ng/mL, comorbid PCOS: Gonadotropin stimulation + growth hormone ($810–$1,200)
- •Age > 40, AMH < 0.4 ng/mL, prior IVF failure: PRP intraovarian injection + modified natural-cycle IVF ($1,750–$2,300)
- •Any age with confirmed FMR1 premutation or POI: Immediate referral for PGT-M–enabled IVF ($5,100–$6,300)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Diminished Ovarian Reserve Medical Vacation Packages
Curated transparent all-inclusive packages combining Diminished Ovarian Reserve treatment with China top medical destinations:
